Citius Pharmaceuticals is trading at $0.50, down 7.60% in pre-market; no new company-specific announcement explaining the decline was found. - The latest identified update was October 26, reporting preliminary LYMPHIR shipments up 120% sequentially. - Shares rose in each of the prior three sessions, including 7.90% on October 28. - Technology was broadly weak, with Nasdaq futures down 1.28%, but no direct link was established; available sources did not confirm volume or a connection to market sentiment.